Clinical Trial Update: Reducing Intracranial atheroSclErosis With Repatha [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating Repatha (evolocumab) for reducing intracranial atherosclerosis in ischemic stroke; study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: University of California, Los Angeles | Conditions: Ischemic Stroke | Phase 4 | Status: TERMINATED | Results posted: 2023-03-15